FLSM
MRTX

Frazier Life Sciences Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Frazier Life Sciences Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-80,000
Closed -$4.7M – 56
2023
Q4 		$4.7M Buy
+80,000
New +$4.5M 0.25% 45

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Frazier Life Sciences Management's MRTX Position: Q1 2024 in Review

Frazier Life Sciences Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 80,000 shares — an estimated $4.7M sold.

Frazier Life Sciences Management first reported a position in MRTX in Q4 2023 and held it in 1 quarter. The position peaked at $4.7M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Frazier Life Sciences Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Frazier Life Sciences Management sold 80,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $4.7M.
  • Frazier Life Sciences Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Frazier Life Sciences Management's Mirati Therapeutics, Inc. Common Stock position peaked at $4.7M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Frazier Life Sciences Management's 13F filing for Q1 2024, filed 15 May 2024.